Differential percentage of serum prostate-specific antigen subforms suggests a new way to improve prostate cancer diagnosis

Prostate

Volumn 70, Issue 1, 2010, Pages 1-9

  Sarrats, Ariadna ^a   Comet, Josep ^b   Tabarés, Glòria ^c   Ramírez, Manel ^b   Aleixandre, R Núria ^b   De Llorens, Rafael ^a   Peracaula, Rosa ^a  

^a UNIVERSITY OF GIRONA   (Spain)

^b HOSPITAL JOSEP TRUETA   (Spain)

^c Protein Chemistry Department   (Germany)

Author keywords

Benign prostatic hyperplasia; Prostate cancer; Prostate specific antigen; Sialic acid; Two dimensional electrophoresis

Indexed keywords

ALPHA 1 ANTICHYMOTRYPSIN; PROSTATE SPECIFIC ANTIGEN; SIALIC ACID; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CANCER DIAGNOSIS; CANCER SCREENING; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; HUMAN; IMMUNOADSORPTION; IMMUNODETECTION; ISOELECTRIC POINT; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; STATISTICAL ANALYSIS; TWO DIMENSIONAL ELECTROPHORESIS; VALIDITY;

AGED; AGED, 80 AND OVER; DIAGNOSTIC TESTS, ROUTINE; FOLLOW-UP STUDIES; HUMANS; ISOENZYMES; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS; TUMOR MARKERS, BIOLOGICAL;

EID: 72849115827     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21031     Document Type: Article

References (33)

1. Bracarda S, de Cobelli O, Greco C, Prayer-Galetti T, Valdagni R, Gatta G, de Braud F, Bartsch G. Cancer of the prostate. Crit Rev Oncol Hematol 2005;56(3):379-396.
2. Lilja H, Ulmert D, Vickers AJ. Prostate-specific antigen and prostate cancer: Prediction, detection and monitoring. Nat Rev Cancer 2008;8(4):268-278.
3. Balk SP, Ko YJ, Bubley GJ. Biology of prostate-specific antigen. J Clin Oncol 2003;21(2):383-391.
4. Stenman UH, Leinonen J, Alfthan H, Rannikko S, Tuhkanen K, Alfthan O. A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: Assay of the complex improves clinical sensitivity for cancer. Cancer Res 1991;51(1):222-226.
5. Mikolajczyk SD, Marks LS, Partin AW, Rittenhouse HG. Free prostate-specific antigen in serum is becoming more complex. Urology 2002;59(6):797-802.
6. Lilja H, Christensson A, Dahlen U, Matikainen MT, Nilsson O, Pettersson K, Lovgren T. Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin. Clin Chem 1991;37(9):1618-1625. (Pubitemid 21905228)
7. Zhang WM, Finne P, Leinonen J, Vesalainen S, Nordling S, Rannikko S, Stenman UH. Characterization and immunological determination of the complex between prostate-specific antigen and alpha2-macroglobulin. Clin Chem 1998;44(12):2471-2479. (Pubitemid 28565659)
8. Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ, Petros JA, Andriole GL. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991;324(17):1156-1161.
9. Laguna P, Alivizatos G. Prostate specific antigen and benign prostatic hyperplasia. Curr Opin Urol 2000;10(1):3-8. (Pubitemid 30066285)
10. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, Minasian LM, Ford LG, Lippman SM, Crawford ED, Crowley JJ, Coltman CA Jr. Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. N Engl J Med 2004;350(22):2239-2246.
11. Damber JE, Aus G. Prostate cancer. Lancet 2008;371(9625):1710-1721.
12. Loeb S, Catalona WJ. What to do with an abnormal PSA test. Oncologist 2008;13(3):299-305.
13. Loeb S, Catalona WJ. Prostate-specific antigen in clinical practice. Cancer Lett 2007;249(1):30-39.
14. Brawer MK, Meyer GE, Letran JL, Bankson DD, Morris DL, Yeung KK, Allard WJ. Measurement of complexed PSA improves specificity for early detection of prostate cancer. Urology 1998;52(3):372-378.
15. Catalona WJ, Southwick PC, Slawin KM, Partin AW, Brawer MK, Flanigan RC, Patel A, Richie JP, Walsh PC, Scardino PT, Lange PH, Gasior GH, Loveland KG, Bray KR. Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging. Urology 2000;56(2):255-260.
16. Mikolajczyk SD, Catalona WJ, Evans CL, Linton HJ, Millar LS, Marker KM, Katir D, Amirkhan A, Rittenhouse HG. Proenzyme forms of prostate-specific antigen in serum improve the detection of prostate cancer. Clin Chem 2004;50(6):1017-1025. (Pubitemid 38725789)
17. Linton HJ, Marks LS, Millar LS, Knott CL, Rittenhouse HG, Mikolajczyk SD. Benign prostate-specific antigen (BPSA) in serum is increased in benign prostate disease. Clin Chem 2003;49(2):253-259. (Pubitemid 36143447)
18. Orntoft TF, Vestergaard EM. Clinical aspects of altered glycosylation of glycoproteins in cancer. Electrophoresis 1999;20(2):362-371. (Pubitemid 29125024)
19. Huber PR, Schmid HP, Mattarelli G, Strittmatter B, van Steenbrugge GJ, Maurer A. Serum free prostate specific antigen: Isoenzymes in benign hyperplasia and cancer of the prostate. Prostate 1995;27(4):212-219.
20. Ohyama C, Hosono M, Nitta K, Oh-eda M, Yoshikawa K, Habuchi T, Arai Y, Fukuda M. Carbohydrate structure and differential binding of prostate specific antigen to Maackia amurensis lectin between prostate cancer and benign prostate hypertrophy. Glycobiology 2004;14(8):671-679. (Pubitemid 39161974)
21. Peracaula R, Tabares G, Royle L, Harvey DJ, Dwek RA, Rudd PM, de Llorens R. Altered glycosylation pattern allows the distinction between prostate-specific antigen (PSA) from normal and tumor origins. Glycobiology 2003;13(6):457-470. (Pubitemid 36665420)
22. Tabares G, Radcliffe CM, Barrabes S, Ramirez M, Aleixandre RN, Hoesel W, Dwek RA, Rudd PM, Peracaula R, de Llorens R. Different glycan structures in prostate-specific antigen from prostate cancer sera in relation to seminal plasma PSA. Glycobiology 2006;16(2):132-145. (Pubitemid 43125969)
23. Charrier JP, Tournel C, Michel S, Dalbon P, Jolivet M. Two-dimensional electrophoresis of prostate-specific antigen in sera of men with prostate cancer or benign prostate hyperplasia. Electrophoresis 1999;20(4-5):1075-1081. (Pubitemid 29222470)
24. Isono T, Tanaka T, Kageyama S, Yoshiki T. Structural diversity of cancer-related and non-cancer-related prostate-specific antigen. Clin Chem 2002;48(12):2187-2194. (Pubitemid 35397561)
25. Jung K, Reiche J, Boehme A, Stephan C, Loening SA, Schnorr D, Hoesel W, Sinha P. Analysis of subforms of free prostate-specific antigen in serum by two-dimensional gel electrophoresis: Potential to improve diagnosis of prostate cancer. Clin Chem 2004;50(12):2292-2301. (Pubitemid 39552164)
26. Tabares G, Jung K, Reiche J, Stephan C, Lein M, Peracaula R, de Llorens R, Hoesel W. Free PSA forms in prostatic tissue and sera of prostate cancer patients: Analysis by 2-DE and western blotting of immunopurified samples. Clin Biochem 2007;40(5-6):343-350. (Pubitemid 46303963)
27. Peter J, Unverzagt C, Hoesel W. Analysis of free prostate-specific antigen (PSA) after chemical release from the complex with alpha(1)- antichymotrypsin (PSA-ACT). Clin Chem 2000;46(4):474-482.
28. Becker C, Wigheden I, Lilja H. Characterization of epitope structure for 53 monoclonal antibodies against prostate-specific antigen. Tumour Biol 1999;20(Suppl 1):13-17.
29. Peter J, Unverzagt C, Lenz H, Hoesel W. Purification of prostate-specific antigen from human serum by indirect immunosorption and elution with a hapten. Anal Biochem 1999;273(1):98-104. (Pubitemid 29400075)
30. Lein M, Jung K, Elgeti U, Petras T, Stephan C, Brux B, Sinha P, Winkelmann B, Schnorr D, Loening S. Comparison of the clinical validity of free prostate-specific antigen, alpha-1 antichymotrypsin-bound prostate-specific antigen and complexed prostate-specific antigen in prostate cancer diagnosis. Eur Urol 2001;39(1):57-64. (Pubitemid 32098471)
31. Liska J, Repiska V, Galbavy S, Polak S, Varga I, Blasko M, Macejova D, Brtko J. Prostate tumours-histological classification and molecular aspects of prostate tumorigenesis. Endocr Regul 2007;41(1):45-57.
32. Harnden P, Shelley MD, Coles B, Staffurth J, Mason MD. Should the Gleason grading system for prostate cancer be modified to account for high-grade tertiary components? A systematic review and meta-analysis. Lancet Oncol 2007;8(5):411-419. (Pubitemid 46621769)
33. Mora LB, Buettner R, Ahmad N, Bassel Y, Jove R, Seigne JD. Prostate adenocarcinoma: Cellular and molecular abnormalities. Cancer Control 2001;8(6):551-561. (Pubitemid 34075935)